Candesartan is a long-used blood-pressure drug with strong evidence for lowering pressure, improving heart-failure outcomes, and preventing migraine, plus stroke reduction in older adults with high blood pressure. Exploratory brain-marker work is early and small. Risks include high blood potassium, low blood pressure symptoms, and kidney stress. Not a general longevity drug without those indications. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Home / ambulatory SBP | Often ~110–120 mmHg if tolerated (individualize) | Tracks primary blood-pressure benefit and hypotension risk |
| Home / ambulatory DBP | Roughly 70–80 mmHg if tolerated | Same as systolic; avoid symptomatic overshoot especially in elderly |
| Serum potassium | ~4.0–4.9 mmol/L (avoid ≥5.5) | Detects hyperkalemia early |
| Creatinine / eGFR | Stable versus baseline; investigate >30% creatinine rise | Detects hemodynamic acute kidney injury |
| Serum sodium | Within lab reference; avoid hyponatremia | Secondary safety with diuretics or combinations |
| Weight (HF) | Stable dry weight | Heart-failure congestion signal |
Cadence: Blood pressure, potassium, and creatinine within 1–2 weeks after start or each dose change, again at about 4 weeks, then every 3–6 months when stable (tighter if chronic kidney disease, heart failure, or interacting drugs); early labs after NSAID courses or dehydrating illness